ReviewCureus2026
Evaluation of the Impact of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) on Long-Term Survival and Morbidity Profile: A Systematic Review of the Peritoneal Carcinomatosis Management.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases: a single-institution experience.Radiology and oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Peritoneal carcinomatosis (PC) has historically represented a terminal stage of abdominal malignancies, with median survival rarely exceeding 6-12 months when managed with systemic chemotherapy alone. Cytoreductive surgery (CRS), combined with hyperthermic intraperitoneal chemotherapy (HIPEC), has emerged as a locoregional therapeutic strategy designed to eradicate both macroscopic and microscopic peritoneal disease. The impact of this combined modality on long-term survival and its related morbidity profile is critically reviewed in this systematic review. A Preferred Reporting Items for Systematic reviews and Meta-Analyses-guided search of PubMed, Scopus, Web of Science, and Embase identified 15 high-quality studies (two randomized controlled trials and 13 cohort studies) comprising 3,247 patients. The synthesis of evidence has proven that the treatment CRS+HIPEC gives a significant survival advantage in carefully selected patients. The median overall survival increased significantly: 30-63 months for colorectal PC, 45-68 months for ovarian PC, and frequently more than 100 months for low-grade appendiceal malignancies, whereas with palliative systemic therapy, it was 12-24 months. However, this benefit is accompanied by considerable morbidity, with significant (Clavien-Dindo III-IV) major complications occurring in 20%-50% and procedure-related mortality occurring in 1%-5%. Survival is largely determined by completeness of cytoreduction (CC-0/1), a Peritoneal Cancer Index below critical thresholds (which vary by tumor type: typically <20 for colorectal, <10-15 for gastric, and higher thresholds for appendiceal tumors), and primary tumor biology. The evidence highlights the fact that CRS+HIPEC is a high-risk, high-reward intervention. Its successful implementation requires rigorous patient selection in high-volume, multidisciplinary centers using standardized protocols that will maximize survival with minimization of significant perioperative risks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.